Table 2 Baseline clinical disease and biomarker characteristics

From: TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer’s disease

Variable

Placebo (n = 214)

Low dose

600 mg q4w (n = 106)

2,000 mg q4w (n = 214)

125 mg q4w (n = 58)

375 mg q12w (n = 58)

Total (n = 116)

MMSE score, mean ± s.d.

25.4 ± 2.3

25.4 ± 2.5

25.4 ± 2.22

25.4 ± 2.4

25.1 ± 2.3

25.4 ± 2.2

CDR global score, n (%)

 0.5

176 (82.2)

40 (69.0)

51 (87.9)

91 (78.4)

87 (82.1)

177 (82.7)

 1

38 (17.8)

18 (31.0)

7 (12.1)

25 (21.6)

19 (17.9)

37 (17.3)

CDR-SB score, mean ± s.d.

3.1 ± 1.5

3.3 ± 1.7

2.6 ± 1.5

2.9 ± 1.6

3.2 ± 1.6

3.0 ± 1.4

ADAS-Cog13 score, mean ± s.d.

26.4 ± 8.4

25.6 ± 8.0

26.2 ± 8.7

25.9 ± 8.3

27.1 ± 8.8

25.3 ± 7.7

FAQ score, mean ± s.d.

8.1 ± 6.0

9.4 ± 7.0

7.4 ± 6.6

8.4 ± 6.8

9.9 ± 6.9

8.1 ± 6.4

ADCS-ADL score, mean ± s.d.

69.3 ± 6.1

68.7 ± 6.4

69.4 ± 7.3

69.1 ± 6.9

67.6 ± 8.0

69.5 ± 6.8

ISLT (z score), mean ± s.d.

−1.9 ± 0.9

−1.9 ± 0.9

−2.0 ± 1.0

−1.9 ± 0.9

−2.1 ± 1.0

−1.9 ± 1.0

ISLR (z score), mean ± s.d.

−2.4 ± 0.7

−2.2 ± 0.9

−2.4 ± 0.7

−2.3 ± 0.8

−2.3 ± 0.8

−2.3 ± 0.8

Tau PETa,b,c SUVR, mean ± s.d.

 Braak I–II composite

1.934 ± 0.5934

1.843 ± 0.6571

1.917 ± 0.6196

1.937 ± 0.5342

 Braak III–IV composite

1.890 ± 0.7223

1.918 ± 0.7770

1.888 ± 0.7062

1.891 ± 0.6801

 Braak V–VI composite

1.742 ± 0.7881

1.754 ± 0.7604

1.741 ± 0.7714

1.766 ± 0.8555

 Medial temporal cortex

2.154 ± 0.7990

2.194 ± 0.9274

2.183 ± 0.8140

2.194 ± 0.7840

 Lateral temporal cortex

2.280 ± 1.0249

2.334 ± 1.1139

2.272 ± 1.0108

2.283 ± 0.9699

 Frontal cortex

1.646 ± 0.7568

1.633 ± 0.7550

1.564 ± 0.7171

1.588 ± 0.7587

Amyloid PETd,e SUVR, mean ± s.d.

 Amyloid-β composite

1.414 ± 0.182

1.417 ± 0.245

1.409 ± 0.170

1.454 ± 0.182

  1. aIn the tau PET sub-study, the placebo group included 118 participants, the low-dose group included 62 participants who received 125 mg (q4w) or 375 mg (q12w) gosuranemab, the 600 mg q4w group included 56 participants and the 2,000 mg q4w group included 121 participants.
  2. bTau PET tracer: [18F]MK-6240.
  3. cTau PET SUVR was computed for composite brain regions included in Braak staging51,52.
  4. dIn amyloid PET imaging, the placebo group included 105 participants, the low-dose group included 57 participants who received 125 mg (q4w) or 375 mg (q12w) gosuranemab, the 600 mg q4w group included 50 participants and the 2,000 mg q4w group included 105 participants.
  5. eAmyloid-β tracer: [18F]florbetapir.
Back to article page